Nemaura Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss Drugs
14 Novembre 2023 - 2:00PM
Nemaura Medical, developer of a daily wear non-invasive glucose
sensor, and digital healthcare programs today announced the UK
launch of its ground-breaking approach to metabolic health and
weight management by integrating continuous glucose monitoring
(CGM) with its behavioral change program, Miboko, complemented by
pharmaceutical interventions using GLP-1 agonists such as Ozempic,
Wegovy and Mounjaro. This innovative offering, featuring education,
lifestyle modifications, dietary guidance, exercise goals, and
cutting-edge glucose monitoring, represents a significant
advancement in personalized weight loss strategies addressing the
metabolic health, obesity and diabetes markets.
Nemaura's program
leverages the power of its world-first daily wear non-invasive CGM
technology, allowing individuals to gain insights into how their
body deals with glucose. By using CGM for just two days per month,
participants can access real-time data on how the drugs, lifestyle,
diet, and exercise are impacting their blood glucose profiles,
empowering them to make informed choices for sustainable
improvements to quality of life.
In pilot studies with
the UK's National Health Service (NHS), Nemaura's program has
demonstrated encouraging outcomes. Early results indicate positive
responses to the integrated approach even in the absence of drug
therapy using GLP-1’s, showcasing the program's potential to
reshape the landscape of personalized health solutions.
The integration of
behaviour change programs, encompassing education on nutrition,
personalized exercise regimens, and lifestyle adjustments,
complements the data-driven approach of CGM. The goal is to provide
individuals with the tools they need to make lasting changes that
support their overall well-being. The incorporation of GLP-1
agonists like Ozempic, Wegovy and Mounjaro adds a powerful layer of
support for individuals seeking effective and sustainable weight
loss.
"The launch of this
integrated program is a turning point in the Company’s history.
Leveraging off positive outcomes observed thus far from the NHS
studies, and the profound impact of GLP-1 therapy globally leads us
to believe we have an optimal offering, with the goal of enabling
the drugs to help kick start weight loss initiatives and then
sustain this through education and sustainable behavioural change,"
said Dr Faz Chowdhury, CEO of Nemaura. Users may now subscribe
directly via the Miboko website at www.Miboko.com
Dr Faz Chowdhury, CEO, will be presenting at,
and host one-on-one meetings with investors, at the Sidoti November
Virtual Investor Conference. Dr Chowdhury’s presentation will begin
at 1:00 pm ET on Wednesday, November 15, 2023 and can be
accessed live here:
https://sidoti.zoom.us/webinar/register/WN_rT_4pTouREiUuM862xQkLA.
Nemaura will also host virtual one-on-ones with investors on
Wednesday and Thursday, November 15-16, 2023. To register for
the presentation or one-on-ones, visit www.sidoti.com/events.
Registration is free.
About Nemaura Medical,
Inc.
Nemaura Medical, Inc. is a medical technology
company developing and wearable diagnostic devices. The company is
currently commercializing sugarBEAT® and proBEAT™. sugarBEAT®,
a CE mark approved Class IIb medical device, is a non-invasive and
flexible continuous glucose monitor (CGM) providing actionable
insights derived from real time glucose measurements and daily
glucose trend data, which may help people with diabetes and
pre-diabetes to better manage, reverse, and prevent the onset of
diabetes. Nemaura has submitted a proposal for a Modular PMA
(Premarket Approval Application) application for sugarBEAT® to
the U.S. FDA, for its generation II, 24 hour sensor.
proBEAT™ is a non-regulated version of sugarBEAT which
combines non-invasive glucose data processed using artificial
intelligence and a digital healthcare subscription service as a
general wellness product as part of its BEAT®diabetes program.
Additionally, Nemaura launched a beta trial of
Miboko, a metabolic health and well-being program using a
non-invasive glucose sensor along with an AI mobile application
that helps a user understand how certain foods and lifestyle habits
can impact one’s overall metabolic health and well-being. Nemaura
believes that up to half the population could benefit from a sensor
and program that monitors metabolic health and well-being.
The Company sits at the intersection of the
global Type 2 diabetes market that is expected to reach nearly $59
billion by 2025, the $50+ billion pre-diabetic market, and the
wearable health-tech sector for weight loss and wellness
applications that is estimated to reach $60 billion by 2023.
For more information, please
visit www.NemauraMedical.com.
Cautionary Statement Regarding
Forward-Looking Statements:
The statements in this press release that are
not historical facts may constitute forward-looking statements that
are based on current expectations and are subject to risks and
uncertainties that could cause actual future results to differ
materially from those expressed or implied by such statements.
Those risks and uncertainties include, but are not limited to, the
launch of proBEAT™ in the U.S., risks related to regulatory
status and the failure of future development and preliminary
marketing efforts, Nemaura Medical’s ability to secure additional
commercial partnering arrangements, risks and uncertainties
relating to Nemaura Medical and its partners’ ability to develop,
market and sell proBEAT™, the availability of substantial
additional equity or debt capital to support its research,
development and product commercialization activities, and the
success of its research, development, regulatory approval,
marketing and distribution plans and strategies, including those
plans and strategies related to both proBEAT™ digital health,
and sugarBEAT®. There can be no assurance that the company will be
able to reach a part of or any of the global market for CGM with
its products/services. The U.S. Food and Drug Administration (the
“FDA”) reserves the right to re-evaluate its decision that
proBEAT™ qualifies as a general wellness product should it
become aware of any issues such as skin irritation or other adverse
events from the device, as well as any misuse impacting patient
safety, and any other reason as the FDA may see fit at its
discretion to determine the product does not fit the definition of
a general wellness product. These and other risks and uncertainties
are identified and described in more detail in Nemaura Medical’s
filings with the United States Securities and Exchange Commission,
including, without limitation, its Annual Report on Form 10-K for
the most recently completed fiscal year, its Quarterly Reports on
Form 10-Q, and its Current Reports on Form 8-K. Nemaura Medical
undertakes no obligation to publicly update or revise any
forward-looking statements.
Investor Relations
Contact:IR@NemauraMedical.com
Nemaura Medical (NASDAQ:NMRD)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Nemaura Medical (NASDAQ:NMRD)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024